Search Results

Suneva Medical, Inc. (“Suneva” or the “Company”) today launched the 30 mL iteration of their Amplifine Platelet Rich Plasma (PRP) gel tubes, which will provide patients and practices with a larger volume of PRP to address varying areas of concern more efficiently.

Suneva Medical, Inc. (“Suneva” or the “Company”), and partner Bimini Health Tech (“Bimini”), today announced that they have received approval from Canada’s Medical Devices Directorate to market the Dermapose® all-in-one fat sizing syringe in Canada. In the U.S., Suneva has also received an additional 510(K) clearance from the U.S. Food and Drug Administration (FDA) for its larger volume 30 mL Amplifine PRP gel tube.

Suneva Medical, Inc., an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, announced that it has appointed Michael Brower as its Chief Financial Officer.

Suneva Medical, Inc. (“Suneva” or the “Company”), an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, and Viveon Health Acquisition Corp. (NYSE American: VHAQ) (“Viveon Health” or “VHAQ”), a special purpose acquisition company, announced today that they have entered into a definitive merger agreement.

Suneva® Medical, Inc., is proud to announce an exciting new partnership that will further its leadership position in regenerative aesthetics.

Suneva® Medical, Inc ., a privately held aesthetics company, is pleased to announce an exclusive strategic partnership to market and distribute Neauvia North America’s Plasma IQ , the first Class 2 FDA cleared plasma energy device throughout North America.

Viveon Health Acquisition Corp. announced that VHAQ filed a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) on July 13, 2022.